AzTrials
AzTrials

Psychiatric DisorderARAVSNCT06499051

Epidemiology of French Sexual Offenders. A Cross-sectional Study

An observational study of Psychiatric Disorder, run by Hôpital le Vinatier at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The epidemiology of sexual offenders has been poorly studied in the literature. A retrospective and prospective study will allow for the examination of the clinical profile of sexual offense perpetrators, risk and recurrence factors, as well as psychiatric or medical treatment. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Psychiatric Disorder
What is being tested?
cognition, impulsivity, emotional regulation, sexuality, diagnosis, sexual violence, motivation, self-esteem, social desirability, and defense mechanisms
How many people
400 participants
Where
1 siteFrance
Study dates
10 May 2024to 1 Sep 2027
How long will I take part?
1 Day
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All sexual offenders who are part of the PFR and meet the inclusion criteria will be invited to participate in this study.

Who may be able to join

  • Adults (age ≥ 18 years).
  • Under injunction of care for a sexual offense.
  • Or Awaiting sentencing for a sexual offense.
  • Or Currently under legal proceedings for a sexual offense.
  • Or Under a legal obligation for care related to a sexual offense.
  • Or Falling within the scope of an alternative to incarceration for a sexual offense.

Who cannot join

  • Patient refusal to participate in the study.
  • Patients with physical or mental incapacity to complete the questionnaires.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • CRIAVS - Centre Hospitalier Le Vinatier

    Bron, 69678

    Sabine Mouchet, Dr, +33 04 37 91 53 09, sabine.mouchet@ch-le-vinatier.fr

    Sabine Mouchet, Dr

    Recruiting

Other trials in France

About this study

Official title: Epidemiology of Sexual Offenders. A Cross-sectional Study of Auvergne-Rhône-Alpes Referral Platforms

The epidemiology of sexual offenders has been poorly studied in the literature. A retrospective and prospective study will allow for the examination of the clinical profile of sexual offense perpetrators, risk and recurrence factors, as well as psychiatric or medical treatment. Since 2015, the Auvergne-Rhône-Alpes region has 8 reference platforms for sexual offense perpetrators, offering personalized assessment according to criteria defined by the Regional Health Agency (ARS). After this assessment, a multidisciplinary meeting is organized to define a tailored care plan. This study, called ARAVS (Auvergne Rhone-Alpes Sexual Offenders), aims to conduct an epidemiological, clinical, and socio-demographic study of patients in these platforms.

Read the detailed description

The Auvergne-Rhône-Alpes region, prompted by the Regional Health Agency (ARS), established a unique system of reference platforms starting in 2015, covering a large part of the region\'s territory. These platforms aim to provide comprehensive care for sexual offense perpetrators in addition to the support provided by the CRIAVS (Resource Centers for Professionals Working with Sexual Offenders). There are currently 8 active reference platforms in the region: in Bourg-en Bresse (Ain), Roanne (Loire), Saint-Etienne (Loire), Lyon (Rhône), Clermont-Ferrand (Puy-de-Dôme), Grenoble (Isère), Annecy (Savoie), and Valence (Drôme).

Given this context, it seems pertinent to implement a retrospective-prospective study of the clinical and epidemiological characteristics of patients treated in these reference platforms to better understand this population. These results will contribute to a better understanding of sexual offense perpetrators in France, as there is limited large-scale clinical data available, and will help tailor care tools to the population being treated in the region. Standardizing the use of common tools, which are currently being used heterogeneously, will also enrich the resources available to clinicians across all platforms by generalizing their use.

The coordinated organization of the reference platform network in the Auvergne-Rhône-Alpes region constitutes a unique care network in France, conducive to a clinical analysis of patients and their care pathways. The project will thus allow for the study of care pathways, the clinical and social profile of sexual offenders, and the identification of risk factors for recurrence among patients based on the data collected.

Being tested
cognition, impulsivity, emotional regulation, sexuality, diagnosis, sexual violence, motivation, self-esteem, social desirability, and defense mechanisms
Keywords
sexual offenses, epidemiology
Medical subject headings
Mental Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • cognition, impulsivity, emotional regulation, sexuality, diagnosis, sexual violence, motivation, self-esteem, social desirability, and defense mechanismsOther

    self-administered questionnaires

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Risk of re-offending and associated factors of the participant

    Sexual offender recidivism risk will be assessed using Static99 scale. The Static-99 (Hanson \& Thornton, 2000) is the most commonly used actuarial risk tool for estimating sexual offender recidivism risk.The risk assessment instrument Static-99R consists of ten items, where all but items 1 and 5 are dichotomous, resulting in 0 or 1 point being added to the total score. The total score, between -3 and 12, results in one out of five recommended risk levels: level I - very low risk (scores of -3 to -2), level II - below average risk (scores of -1 to 0), level III - average risk (scores of 1 to 3), level IVa - above average risk (scores of 4 to 5), and level IVb - well above average risk (scores of 6+).

    Measured: From May 2024 to May 2027

Secondary outcomes (8)
  1. Impulsivity of the participant

    Impulsivity will be assessed using the UPPS-P ( Impulsive Behavior Scale) scale. Participants are asked to consider acts/incidents during the last 6 months when rating their behavior and attitudes on a 4-point scale, in which 1-Agree strongly, 2-Agree some, 3-Disagree some, 4-Disagree strongly. This is a 59-item scale measuring 5 impulsivity components: negative urgency, positive urgency, lack of premeditation, lack of perseverance, and sensation seeking.Scores are presented for each of five subscales, plus a total impulsivity score.In addition to the raw scores, the mean is calculated for the items on each subscale, from 1 to 4, where 1 indicates that the respondent did not endorse impulsive answers, and 4 indicates a high level of self-reported impulsivity.

    Measured: From May 2024 to May 2027 (cross-sectional study)

  2. Cognition of the participant

    Cognition will be assessed using The Patient Competency Rating Scale (PCRS). The PCRS consists of 30 items, each scored on a scale of 1 to 5, making the total score range from 30 to 150. The higher scores indicate greater competency in the list of skills on the test.

    Measured: From May 2024 to May 2027 (cross-sectional study)

  3. Emotional status of the participant

    Emotional status will be assessed using theTAS-20 (Toronto Alexithymia Scale) scale. The TAS-20 is a self-report scale that is comprised of 20 items. Items are rated using a 5-point Likert scale whereby 1 = strongly disagree and 5 = strongly agree. There are 5 items that are negatively keyed (items 4, 5, 10, 18 and 19). The total alexithymia score is the sum of responses to all 20 items.The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.

    Measured: From May 2024 to May 2027 (cross-sectional study)

  4. Diagnosis of the participant

    Diagnosis will be assessed using the PCL-R scale (Psychopathy Checklist Revised). The scale includes 2 factors. Factor 1 is a measure of Emotional Detachment (e.g., superficial charm, manipulativeness, shallow affectivity, absence of guilt or empathy). Factor 2 is a measure of Antisocial Behavior (deviance from an early age, aggression, impulsivity, irresponsibility, proneness to boredom). There is also a total score. A total score of 10-19 diagnoses an individual as midly psychopathic. A score of 20-29 diagnoses them as moderately psychopathic. a score of 30-40 diagnoses them as severely psychopathic.

    Measured: From May 2024 to May 2027 (cross-sectional study)

  5. Cognitive distorsions of the participant

    Cognitive distorsions will be assessed using the bumby RAPE (BRS) and MOLEST (BMS) scales. The MOLEST scale is composed of 38 items and the RAPE scale is composed of 36 items scored on a 4-point Likert scale from strongly agree to strongly disagree. The BMS consists of38 items with a range of total scores being a minimum of 38 and a maximum of 152, and the BRS consists of 36 items with a total score ranging from 36 to 144.

    Measured: From May 2024 to May 2027 ((cross-sectional study)

  6. Pedophilic Interests of the participant

    pedophilic interests will be assessed using the Revised Screening Scale for Pedophilic Interests (SSPI-2). The SSPI-2 score ranges from zero to five, with higher scores indicating sexual interest in children.

    Measured: From May 2024 to May 2027 ((cross-sectional study)

  7. Motivation of the participant

    Motivation will be assessed using the URICA (University of Rhode Island Change Assessment Scale) scale. This is is a 32 item self-report measure that includes 4 subscales measuring the stages of change: Precontemplation, Contemplation, Action, and Maintenance. Responses are given on a 5 point Likert scale ranging from (1=strong disagreement to 5=strong agreement), An overall readiness to change score is calculated using a weighted average of the four sub-scores, where 14 is the maximum possible score. A higher score corresponds to increased readiness to change

    Measured: From May 2024 to May 2027 ((cross-sectional study)

  8. Self-esteem of the participant

    Self-esteem will be assessed using the Rosenberg scale. The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.

    Measured: From May 2024 to May 2027 (cross-sectional study)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jul 2024
  2. Study start10 May 2024
  3. Primary completion1 Jun 2027 (estimated)
  4. Study completion1 Sep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Other
Enrolment
400 participants (estimated)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT06499051
Sponsor's protocol ID
2023-A01205-40
Acronym
ARAVS
Status last verified
Jul 2025
First submitted
10 Jun 2024
Last updated
17 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Psychiatric Disorder, run by Hôpital le Vinatier at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sabine Mouchet, Dr (+33 4 37 91 53 09, sabine.mouchet@ch-le-vinatier.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Risk of re-offending and associated factors of the participant (time frame: From May 2024 to May 2027). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in